Active Filter(s):
Details:
BXQ-350 increases ceramides and decreases sphingosine-1-phosphate (S1P) to selectively target tumor cells and only tumor cells. It is being developed for relapsed solid tumors.
Lead Product(s): BXQ-350
Therapeutic Area: Oncology Product Name: BXQ-350
Highest Development Status: Phase I Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 23, 2023
Details:
BXQ-350 is a novel anti-neoplastic therapeutic agent configured from two components: Saposin C (SapC), an expressed (human) lysosomal protein, and the phospholipid dioleoylphosphatidyl-serine (DOPS), a cell membrane phospholipid used for solid tumors and gliomas.
Lead Product(s): Saposin C,Dioleoyl Phosphatidylserine
Therapeutic Area: Oncology Product Name: BXQ-350
Highest Development Status: IND Enabling Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 29, 2021
Details:
The presentations will focus on BXQ-350, Bexion's first-in-class agent composed of the multifunctional, lysosomal activator protein Saposin C and phosphatidylserine, for refractory solid tumors and high-grade gliomas.
Lead Product(s): BXQ-350
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase I Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 13, 2020
Details:
U.S FDA has granted Bexion Pharmaceuticals an Orphan Drug Designation for its proprietary drug, BXQ-350, for the treatment of malignant glioma, including diffuse intrinsic pontine glioma (DIPG).
Lead Product(s): Saposin C-dioleoylphosphatidylserine
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase I Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 07, 2020